18264-Gall Bladder Cancer-NA-113

Gall Bladder Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number:

  • Address

3410 Worth Street, Suite 400
Dallas, TX 75246
P: (214) 370-1300

Search by practice name, trial titles, indicators and specific disease types.